Shenzhen BORUI Pharmaceutical Technology Co., Ltd. and Shenzhen Futian Biopharmaceutical Service Center started the test operation
Nowadays, the Shenzhen Futian Biopharmaceutical Service Center, which is constructed and operated by Shenzhen BORUI Pharmaceutical Technology Co., Ltd. (Shenzhen BORUI), a wholly-owned subsidiary of Guangzhou Boji Medical Biotechnological Co., Ltd. (Guangzhou Boji), has completed all preparations and officially started the test operation.
In February last year, Shenzhen Futian Government introduced Guangzhou Boji, the largest CRO enterprise in South China, into operation to build a public service platform for drug R&D in Futian.
The relevant person in charge of Shenzhen BORUI said that under the guidance and support of Shenzhen Futian Government, Guangzhou Boji established Shenzhen BORUI Pharmaceutical Technology Co., Ltd., planned and designed from a high starting point, built a new innovative drug R&D service platform, and recruited top experts in innovative drug R&D from all over the world, so as to enhance the international ability of the service team, and strive to build an integrated platform for innovative drug R&D services in Great Bay Area.
Wutong tree just planted, Phoenix came immediately.
As an incubator platform, Shenzhen Futian Biopharmaceutical Service Center has attracted nearly 20 biotechs engaged in drug R&D and medical device development to settle down in less than one year.
The relevant person in charge of Shenzhen BORUI said that the company will rely on the parent company Guangzhou Boji, make full use of the core location advantages of the International Pharmaceutical Industrial Park and the policy advantages of Shenzhen, and actively cooperate with the government to provide professional services for entrepreneurial and innovative scientists and biotechs, so as to jointly build a new height of bio-industry in Great Bay Area.
About Shenzhen Futian Biopharmaceutical Service Center
Shenzhen Futian Biopharmaceutical Service Center is located at No.1 Haihong Road, Futian Free Trade Zone, Shenzhen. It is very advantageous in geographical location, close to the Great Bay Area sub center of NMPA (sub-CDE and sub-CMDE), and across the bank facing Shenzhen Hong Kong Science and Technology Innovation Cooperation Zone (Hong Kong Lok Ma Chau Hetao District). Innovative enterprises settled in the center have zero distance communication with angel investors and venture capital institutions, and enjoy various innovation policy dividends and supports in Shenzhen.
Shenzhen Futian Biopharmaceutical Service Center mainly undertakes the medicinal chemistry, chemical / biological analysis (large and small molecules), in vitro and in vivo pharmacological efficacy, et. al. in the innovative drug R&D, and will strive to build a advantage platform in the fields of target verification and confirmation, introduction of cutting-edge technology into medicinal chemistry, cell / gene therapy, and translational medicine platforms.